Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

Completed · Phase 3

Conditions studied: Pantothenate Kinase-Associated Neurodegeneration

In brief

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

Key facts

Study ID

NCT02174848

Run by

ApoPharma

People needed

68

Starts

2014-06-01

Expected to finish

2018-03-16

Last updated by the study team

2020-08-25

Who can join

Age: 5 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completed study TIRCON2012V1

You may not qualify if…

• Withdrew from the study TIRCON2012V1 for reasons of safety
• Plan to participate in another clinical trial at any time from the day of enrolment until 30 days post-treatment in the current study

Where it is running

• UCSF Benioff Children's Hospital Oakland — Oakland, California, United States
• Klinikum der Universität München — Munich, Germany
• Foundation Neurological Institute C. Besta — Milan, Italy
• Newcastle University Institute of Human Genetics — Newcastle upon Tyne, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.